ClinicalTrials.gg
WithdrawnNCT01933061Updated Feb 4, 2014

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

A Phase 2 interventional study of Abraxane and Abraxane in Metastatic Melanoma, sponsored by Celgene Corporation. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-04.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Strategic decision not to proceed with the opening of this study. There are no concerns over the safety or quality of the investigational products involved.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing Albumin-Bound Paclitaxel in Melanoma — none open to participants now, none under way, none of them phase 3. Albumin-Bound Paclitaxel · Melanoma.

Enrollment
13th of 15
0 · median 30
Started
2014
with 2 others
Phase 2
8 of 16
none open now
Registered
11th of 16
by date
Lead sponsor
1 of 16
Celgene Corporation

Among the 16 studies testing Albumin-Bound Paclitaxel in Melanoma, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2014, is one of 8 in phase 2, and was the 11th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 16 studies testing Albumin-Bound Paclitaxel in Melanoma is open now. The open studies under Melanoma, anywhere →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing Albumin-Bound Paclitaxel in Melanoma as a file.
02

Study summary

A phase 2, open-label randomized, multicenter trial to compare CC-486 in combination with Abraxane administered weekly with respect to overall survival, objective tumor response rate and Progression-Free Survival (PFS) in participants diagnosed with metastatic malignant melanoma.

Read the detailed description

The study will consist of the following phases:

  • Screening (Baseline) Assessments: Performed within 21 days of randomization.
  • Randomization: Subjects will be randomized within 21 days of starting their Baseline assessments.
  • Treatment: Therapy may continue in the absence of clinically significant disease progression and unacceptable toxicity.
  • Response Assessments: Subjects will be evaluated by investigators for CR, PR, stable or progressive disease every 6 weeks from the start of treatment until progressive disease is documented.

Responders and subjects with stable disease (SD) should continue on study unless they develop unacceptable toxicity, they start a new anticancer therapy, withdrawal of consent, physician decision or death.

  • End of Study (EOS)/Treatment Evaluation: At the time subjects are removed from study, laboratory and clinical evaluations will be performed.
  • Follow-up for Disease Progression:

    • Subjects who stop treatment prior to developing disease progression should be followed without further treatment until progressive disease is documented or until the treating physician feels additional treatment is required.
  • Follow-up for Survival:

    • Post study, subject survival status will be monitored on a monthly basis for 6 months from discontinuation from the study and every 3 months thereafter, until death or study termination in all subjects.
03

Conditions studied

  • Metastatic Melanoma

Browse trials for

Keywords

  • Skin cancer, Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. or cytologically confirmed cutaneous BRAF wild-type malignant melanoma with evidence of (Stage IV).

      1. No prior cytotoxic chemotherapy for metastatic malignant melanoma is permitted. No prior cytotoxic chemotherapy is permitted.
      • Up to one prior regimen with the following classes of agents is permitted:

        o Targeted biologic agents (e.g. interleukin 2 [IL-2], granulocyte macrophage colony stimulating factor [GM-CSF], other cytokines or unarmed monoclonal antibodies)

        o Targeted small molecule inhibitors (e.g., kinase inhibitors, heat shock protein [HSP] inhibitors, etc.).

        • (e.g. anti-CTLA4, anti-PD1, anti-PD-L1).
        • Prior adjuvant therapy with interferon and/or vaccines is permitted.
      • Prior treatments should be completed 4 weeks prior to enrollment in the study (ie, randomization).

        1. Male or non-pregnant and non-lactating female, and ≥ 18 years of age at the time of signing the document.
      • If heterosexually active, the subject must agree to use medical doctor-approved throughout the study, and for 6 months after last dose of study drug.

        1. History of in the last 5 years; subjects with prior history of in situ cancer or basal or squamous cell skin cancer are eligible.
      • Subjects with other malignancies are eligible if they were cured by surgery (with or without radiotherapy) and have been continuously disease-free for at least 5 years.

        1. Radiographically-documented (defined by the presence of at least one radiographically documented measurable lesion including measurable cutaneous metastasis).
        1. Adequate haemtological and biochemical parameters:
      • ≥ 1.5 x 109 cells/L.
      • ≥ 100 x 109 cells/L.
      • ≥ 9 g/dL.
      • (SGOT) or ALT (SGPT) ≥ 2.5x (ULN);

        o ≤ 5.0 x ULN if hepatic metastases present.

      • Total ≤ ULN. Creatinine ≤ 1.5 mg/dL. 8. performance status 0 to 1.

Exclusion criteria

Exclusion Criteria:

    1. History of or current evidence of symptomatic (brain Computed Tomography (CT)/Magnetic Resonance Imaging (MRI) is needed to exclude brain metastasis), including .

      1. Subject has pre-existing peripheral neuropathy of National Cancer Institute NCI (NCI CTCAE) Scale of Grade ≥ 2.
      1. Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Abraxane 150 mg/m² Intravenous (IV)

    Drug: Abraxane

  • Experimental
    CC-486 orally plus Abraxane IV

    Drug: Abraxane

Interventions

  • Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle

    Also known as: nab-paclitaxel, ABI-007

  • Abraxane 150 mg/m\^2 intravenously on Days 1, 8, and 15 of a 28-day cycle

    Also known as: nab-paclitaxel, ABI-007

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the time from randomization date to disease progression according to RECIST response guideline

    Time frame: Up to 24 months

Secondary outcomes

  1. Overall survival (OS)

    OS is defined as the time from the date of randomization to the date of death.

    Time frame: Up to 24 months

  2. PFS

    PFS based on investigator assessment; PFS is defined as the time from randomization date to disease progression according to RECIST response guideline

    Time frame: Up to 24 months

  3. Objective Response Rate (ORR)

    Number (%) of subject who achieve an objective complete or partial response.

    Time frame: Up to 24 months

  4. Disease Control Rate (DCR)

    Number (%) of subject with Stable Disease (SD) ≥ for 18 weeks or complete or partial response.

    Time frame: Up to 24 months

  5. Safety

    Incidence and severity of Adverse events (AE) will be analyzed in terms of treatment-emergent AEs defined to be any AE that begin or worsen in severity after study drug initiation.

    Time frame: Up to 24 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2013
First posted
Aug 30, 2013
Start
Jan 2014
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Last update
Feb 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01933061
Responsible party
Sponsor
First posted
Aug 30, 2013
Start date
Jan 2014
Primary completion
Jan 2014
Completion
Jan 2014
Last update
Feb 4, 2014

Study contacts

Kirsten Hege, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion